Corbacioglu, Selim and Jabbour, Elias J. and Mohty, Mohamad (2019) Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25 (7). pp. 1271-1280. ISSN 1083-8791, 1523-6536
Full text not available from this repository. (Request a copy)Abstract
Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) most commonly associated with high-intensity chemotherapies. The development of VOD/SOS may be rapid and unpredictable, and the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly recognized. The reporting of new retrospective study data for adults and children and the emergence of novel anticancer therapies that may increase the risk of VOD/SOD also necessitate updates on risk factors, as provided in this review. The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data. Non transplantation-related chemotherapies associated with increased risk for VOD/SOS include oxaliplatin and 5-fluorouracil chemotherapies. The novel antibody drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin are now reported in product labeling to pose risks for VOD/SOS based on clinical trial data; an expert consensus panel has issued recommendations for risk reduction measures with inotuzumab ozogamicin treatment, including VOD/SOS prophylaxis and limitation to <= 2 inotuzumab ozogamicin treatment cycles. A wide range of biomarkers, including genetic, hematologic, hepatic, and inflammatory factors, as well as novel diagnostic techniques such as thromboelastography and measures of liver stiffness, may further enhance future risk calculation for VOD/SOS, although none has been widely adopted. Continual monitoring for and recognition of VOID/SOS risk factors are essential for optimal management of this complication. (C) 2019 American Society for Blood and Marrow Transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; OXALIPLATIN-BASED CHEMOTHERAPY; SINUSOIDAL OBSTRUCTION; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; ADULT PATIENTS; OCCLUSIVE DISEASE; EUROPEAN-SOCIETY; Veno-occlusive disease/sinusoidal obstruction syndrome; Risk factors; Primary chemotherapy; Antibody drug conjugates; Biomarkers |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Petra Gürster |
| Date Deposited: | 31 Mar 2020 08:57 |
| Last Modified: | 31 Mar 2020 08:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26721 |
Actions (login required)
 |
View Item |
